ArticleBMC infectious diseases2025
Socio-demographic determinants of COVID-19 vaccination status among people living with HIV; a cross-sectional study in selected regions in Tanzania.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Determinants of non-compliance with additional booster doses of the SARS-CoV-2 vaccine in people living with HIV (PWH): An observational study based on a behavioral and epidemiological survey in Rome (Italy).Human vaccines & immunotherapeutics · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPublic Health and Social Measures (PHSM) are among the commonly used methods to prevent the spread of Corona Virus Disease of 2029 (COVID-19). Vaccination has also been an integral component of infectious disease prevention and control and it has been used widely to protect humans against some of the very serious diseases such as COVID-19. People living with HIV (PLHIV) are known to be more vulnerable to the severest form of COVID-19 than the general population. Other groups of people likely to get the severe form of COVID-19 include the elderly and those with co-morbidities such as cancers, cardiovascular diseases, diabetes, etc.
objectivesThe main objective of the study was to establish socio-demographic factors that could determine COVID-19 vaccination status among PLHIV in selected regions in mainland Tanzania and to provide insight into ways to increase COVID-19 vaccine coverage in Tanzania.
methodsA facility-based cross-sectional study was conducted between March and April 2022 among PLHIV in four conveniently sampled regions of Tanzania namely Kagera, Tabora, Geita, and Dar es Salaam. A total of 25 Care and Treatment Centres (CTCs) were randomly selected with a probability proportion by size in each region. In each CTC, 11 PLHIV eligible for vaccination were systematically selected to participate in the study. Face-to-face interviews were conducted using a structured questionnaire and Open Data Kit (ODK) software was used to record and transfer data to a designated server. Data cleaning and analysis were done using Stata version 14.0. A chi-square test was used to assess the association between socio-demographic characteristics and COVID-19 vaccination status. A generalized linear mixed-effects model was fitted to determine factors associated with COVID-19 vaccination status.
resultsOut of 1,100 PLHIV interviewed, 696 (63.3%) were found to be vaccinated against COVID-19. Level of education, age, occupation, employment status, location, and level of health facilities were found to be significantly associated with of COVID-19 vaccination status among PLHIV in the study areas. PLHIV who had college and university education, elderly, farmers, and those employed and living in a rural setting were found to be more likely to be vaccinated than other comparison groups in the categories analyzed.
conclusionThis facility-based cross-sectional study showed a higher COVID-19 vaccination rate (63.3%) among PLHIV compared to the general population. This could be explained by efforts by both public and private sectors to promote COVID-19 vaccination among PLHIV have had a positive impact on vaccination uptake. However, to meet the World Health Organization (WHO) target of 60% vaccination coverage, additional tailored interventions are required. These should include specific strategies that could be effective in urban areas, expanding vaccination access by increasing the number of vaccinations centers, supporting those who face barriers to vaccination, and actively engaging not only elderly individuals but also middle-aged and younger members of the community and PLHIV networks. Moreover, greater involvement from higher levels of health service provision, such as health centers and hospitals, will be likely increase vaccination coverage and address the unmet needs of this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.